# LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

> **NCT02131155** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Placebo
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02131155
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-17
- **Primary completion:** 2016-08-22
- **Final completion:** 2016-08-22
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02131155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02131155, "LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02131155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*